Sei Investments Co. lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 18.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,141 shares of the medical research company’s stock after buying an additional 9,026 shares during the period. Sei Investments Co. owned approximately 0.07% of NeoGenomics worth $762,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of the company. Quantitative Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the first quarter valued at about $100,000. OMERS ADMINISTRATION Corp purchased a new position in shares of NeoGenomics in the first quarter valued at approximately $152,000. FDx Advisors Inc. boosted its stake in shares of NeoGenomics by 19.9% in the first quarter. FDx Advisors Inc. now owns 30,644 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 5,091 shares during the period. WINTON GROUP Ltd purchased a new position in shares of NeoGenomics in the first quarter valued at approximately $338,000. Finally, Trexquant Investment LP purchased a new position in shares of NeoGenomics in the first quarter valued at approximately $361,000. 81.06% of the stock is currently owned by hedge funds and other institutional investors.
NEO has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Thursday, July 19th. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 10th. Stephens restated a “buy” rating and set a $15.00 price objective on shares of NeoGenomics in a research report on Tuesday, June 26th. BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of NeoGenomics in a research report on Thursday, June 21st. Finally, First Analysis set a $16.00 price objective on shares of NeoGenomics and gave the stock a “buy” rating in a research report on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $19.25.
In other news, EVP Steven C. Jones sold 44,600 shares of the company’s stock in a transaction on Monday, July 30th. The shares were sold at an average price of $14.01, for a total transaction of $624,846.00. Following the transaction, the executive vice president now directly owns 241,815 shares of the company’s stock, valued at approximately $3,387,828.15. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven C. Jones sold 203,500 shares of the company’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $14.00, for a total transaction of $2,849,000.00. Following the transaction, the insider now directly owns 241,815 shares in the company, valued at $3,385,410. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.
Shares of NeoGenomics stock traded down $0.16 during trading on Friday, reaching $14.31. The company’s stock had a trading volume of 495,810 shares, compared to its average volume of 480,709. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.74 and a quick ratio of 1.59. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of 238.50 and a beta of 0.42. NeoGenomics, Inc. has a fifty-two week low of $7.08 and a fifty-two week high of $15.63.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 24th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01. The company had revenue of $67.70 million for the quarter, compared to analysts’ expectations of $66.40 million. NeoGenomics had a negative net margin of 0.98% and a negative return on equity of 0.36%. NeoGenomics’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.04 EPS. Analysts anticipate that NeoGenomics, Inc. will post 0.08 earnings per share for the current year.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Read More: Ex-Dividend
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.